CEMIP is reported to involve prostate cancer proliferation,[50] migration, and invasion.[51] It was found that CEMIP promotes anoikis resistance by enhancing protective autophagy[52,53] and facilitates ferroptosis resistance by promoting cystine uptake[54] in prostate cancer cells during ECM, thus promoting metastasis formation. Here, CEMIP is linked to prostate carcinoma.